Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …
Faces of ALS: My Story of Service
ALS is called a rare disease. But for reasons not yet known, veterans are twice as likely to be diagnosed with ALS compared to the general public. Last week, we as a nation honored our brave veterans for their sacrifice …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
November 2020 Events eNews
Go All in for ALS this Friday Night A 3 day, 2 night stay at a charming cottage nestled in the Indiana Dunes could be yours! This magical getaway is just one of the silent auction prizes offered at our …
November 2020 Foundation eNews
Empowering through ALS Education We are excited to launch our new online learning series aimed at empowering our ALS community through the latest information and insights. Educational webinars and interactive Q&A’s covering a diverse array of topics, from telemedicine to …
